All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99


Ciprofloxacin Hydrochloride Encapsulated into PLGA Nanoparticles for Drug Delivery Application: Fractional Factorial Design

DOI: 10.4236/oalib.1104294, PP. 1-14

Subject Areas: Pharmacology, Medicinal Chemistry

Keywords: Ciprofloxacin Hydrochloride, PLGA Nanoparticles, Drug Recovery, Double Emulsion Solvent Evaporation, Fractional Factorial Design

Full-Text   Cite this paper   Add to My Lib


Over several decades, poly (lactic-co-glycolic acid) (PLGA) have been widely used as Micro-and Nano-carriers of therapeutic agents for drug delivery applications. However, encapsulation process of therapeutic agents into PLGA Nanoparticles (NPs) necessitates a defined step to understand the effects and interactions of parameters involved in production process. In pharmaceutics formulations, compared to one factor at a time (OFAT) approach, statistical design of experiments (DOE) supersedes OFAT approach due to limited number of experiments required to investigate effects and interactions of a process parameters. The major objectives of the present study were to: 1) prepare and understand the effect of selected formulation parameters on particles size and drug recovery of PLGA NPs encapsulating Ciprofloxacin Hydrochloride (Cip-HCl) using a fractional factorial design (FFD) as a DOE approach; 2) understand the in-vitro release of Cip-HCl from PLGA NPs. Cip-HCl loaded PLGA were prepared by W1/O/W2 double emulsion solvent evaporation (DESE) method using poly-vinyl alcohol as a stabilizer. The Sizes of NPs were within 202 nm to 530 nm and percentage Cip-HCl recovered from dried NPs were within 1.7% w/w to 15.7% w/w. Increasing concentrations of PLGA and Cip-HCl was observed to increase NPs size. Increasing PVA concentration was observed to either reduce or increase NPs size. Increasing PLGA concentration was observed to increase the amount of Cip-HCl recovered. Within 1-24 hours, optimized formulations shows a controlled release of Cip-HCl from PLGA NPs.

Cite this paper

Adebileje, T. , Adebileje, S. and Aye, P. O. (2018). Ciprofloxacin Hydrochloride Encapsulated into PLGA Nanoparticles for Drug Delivery Application: Fractional Factorial Design. Open Access Library Journal, 5, e4294. doi:


[1]  Alonso, M.J. (2004) Nanomedicines for Overcoming Biological Barriers. Biomedicine & Pharmacotherapy, 58, 168-172.
[2]  Ayodele, A.T., et al. (2017) Bio-interface Research in Applied Chemistry. Ultrasound, 69, 70.
[3]  Prego, C., et al. (2005) Nanomedicines for Overcoming Biological Barriers: Nanoparticles as a Carrier for Intestinal Drug Absorption. 2nd NanoSpain Workshop, Barcelona, March 14-17 2005.
[4]  Chin, N.-X. and Neu, H.C. (1984) Ciprofloxacin, a Quinolone Carboxylic Acid Compound Active against Aerobic and Anaerobic Bacteria. Antimicrobial Agents and Chemotherapy, 25, 319-326.
[5]  Puga, A.M., et al. (2012) Hot Melt Poly-ε-Caprolactone/Poloxamine Implantable Matrices for Sustained Delivery of Ciprofloxacin. Acta Biomaterialia, 8, 1507-1518.
[6]  Lesk, M.R., et al. (1993) The Penetration of Oral Ciprofloxacin into the Aqueous Humor, Vitreous, and Subretinal Fluid of Humans. American Journal of Ophthalmology, 115, 623-628.
[7]  Chaudhry, N.A., et al. (2000) Xanthomonas maltophilia Endophthalmitis after Cataract Surgery. Archives of Ophthalmology, 118, 572-575.
[8]  Astete, C.E. and Sabliov, C.M. (2006) Synthesis and Characterization of PLGA Nanoparticles. Journal of Biomaterials Science, Polymer Edition, 17, 247-289.
[9]  Breda, S.A., et al. (2009) Solubility Behavior and Biopharmaceutical Classification of Novel High-Solubility Ciprofloxacin and Norfloxacin Pharmaceutical Derivatives. International Journal of Pharmaceutics, 371, 106-113.
[10]  Kasim, N.A., et al. (2004) Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification. Molecular Pharmaceutics, 1, 85-96.
[11]  Dillen, K., et al. (2006) Evaluation of Ciprofloxacin-Loaded Eudragit RS100 or RL100/PLGA Nanoparticles. International Journal of Pharmaceutics, 314, 72-82.
[12]  Adebileje, T., Valizadeh, A. and Amani, A. (2017) Effect of Formulation Parameters on the Size of PLGA Nanoparticles Encapsulating Bovine Serum Albumin: A Response Surface Methodology. Journal of Contemporary Medical Sciences, 3, 306-312.
[13]  Dejaegher, B. and Vander Heyden, Y. (2011) Experimental Designs and Their Recent Advances in Set-Up, Data Interpretation, and Analytical Applications. Journal of Pharmaceutical and Biomedical Analysis, 56, 141-158.
[14]  Zimmer, A. and Kreuter, J. (1995) Microspheres and Nanoparticles Used in Ocular Delivery Systems. Advanced Drug Delivery Reviews, 16, 61-73.
[15]  Song, X., et al. (2008) PLGA Nanoparticles Simultaneously Loaded with Vincristine Sulfate and Verapamil Hydrochloride: Systematic Study of Particle Size and Drug Entrapment Efficiency. International Journal of Pharmaceutics, 350, 320-329.
[16]  Budhian, A., Siegel, S.J. and Winey, K.I. (2007) Haloperidol-Loaded PLGA Nanoparticles: Systematic Study of Particle Size and Drug Content. International Journal of Pharmaceutics, 336, 367-375.
[17]  Haznedar, S. and Dortunc, B. (2004) Preparation and in Vitro Evaluation of Eudragit Microspheres Containing Acetazolamide. International Journal of Pharmaceutics, 269, 131-140.
[18]  Hoffart, V., et al. (2002) Low Molecular Weight Heparin-Loaded Polymeric Nanoparticles: Formulation, Characterization, and Release Characteristics. Drug Development and Industrial Pharmacy, 28, 1091-1099.
[19]  Sahana, B., et al. (2010) Development of Biodegradable Polymer Based Tamoxifen citrate Loaded Nanoparticles and Effect of Some Manufacturing Process Parameters on Them: A Physicochemical and in-vitro Evaluation. International Journal of Nanomedicine, 5, 621-630.
[20]  McCall, R.L. and Sirianni, R.W. (2013) PLGA Nanoparticles Formed by Single or Double-Emulsion with Vitamin E-TPGS. Journal of Visualized Experiments, 82, e51015.
[21]  Dillen, K., et al. (2004) Factorial Design, Physicochemical Characterisation and Activity of Ciprofloxacin-PLGA Nanoparticles. International Journal of Pharmaceutics, 275, 171-187.
[22]  Jiao, Y., et al. (2002) In Vitro and in Vivo Evaluation of Oral Heparin-Loaded Polymeric Nanoparticles in Rabbits. Circulation, 105, 230-235.
[23]  Panyam, J., et al. (2003) Polymer Degradation and in Vitro Release of a Model Protein from Poly (D, L-lactide-co-glycolide) Nano-and Microparticles. Journal of Controlled Release, 92, 173-187.
[24]  Korsmeyer, R.W. and Peppas, N.A. (1981) Effect of the Morphology of Hydrophilic Polymeric Matrices on the Diffusion and Release of Water Soluble Drugs. Journal of Membrane Science, 9, 211-227.


comments powered by Disqus

Contact Us


微信:OALib Journal